Syncom Formulations Valuation Shifts Signal Growing Price Pressure Amid Sector Dynamics

Valuation Metrics Reflect Elevated Pricing

As of 26 May 2026, Syncom Formulations trades at a P/E ratio of 19.50, a level that has pushed its valuation grade from fair to expensive. This marks a significant change from previous assessments, signalling that investors are now paying a premium for the company’s earnings relative to its historical valuation band. The price-to-book value ratio stands at 3.59, further underscoring the market’s willingness to assign a higher multiple to the company’s net assets.

Other valuation multiples also indicate a stretched price level. The enterprise value to EBITDA (EV/EBITDA) ratio is 17.80, while the EV to EBIT ratio is 19.44, both suggesting that Syncom’s operational earnings are being valued at a premium compared to typical industry standards. The EV to capital employed ratio of 4.54 and EV to sales of 2.82 reinforce this elevated valuation stance.

Interestingly, the PEG ratio remains low at 0.36, which could imply that the market expects strong earnings growth to justify the current multiples. However, this metric alone does not offset the broader picture of an expensive valuation.

Peer Comparison Highlights Relative Positioning

When compared with its peers in the Pharmaceuticals & Biotechnology sector, Syncom Formulations’ valuation appears more moderate but still on the expensive side. For instance, Bliss GVS Pharma trades at a higher P/E of 25.71 and EV/EBITDA of 19.58, while Kwality Pharma and NGL Fine Chem are classified as very expensive with P/E ratios of 34.06 and 36.97 respectively.

On the other hand, companies like Venus Remedies and Lincoln Pharma maintain fair valuation grades with P/E ratios of 19.92 and 16.34 respectively, and significantly lower EV/EBITDA multiples. This suggests that while Syncom is not the most expensive in its peer group, it has moved beyond the fair value range, warranting caution among investors.

Notably, Fredun Pharma and Jagsonpal Pharma exhibit even higher valuations, with P/E ratios exceeding 30 and EV/EBITDA multiples above 17, indicating a sector-wide trend of premium pricing for select pharmaceutical stocks.

Financial Performance and Returns Contextualise Valuation

Syncom Formulations’ return on capital employed (ROCE) stands at a robust 23.35%, while return on equity (ROE) is 18.41%, indicating efficient utilisation of capital and shareholder funds. These metrics support the premium valuation to some extent, reflecting the company’s operational strength and profitability.

However, the stock’s price performance over various time horizons presents a mixed picture. The company has delivered a strong 1-week return of 13.87% and a 1-month gain of 17.68%, significantly outperforming the Sensex, which rose 1.56% and declined 0.23% respectively over the same periods. Year-to-date, Syncom has gained 11.00%, while the Sensex has fallen 10.25%, further highlighting the stock’s recent momentum.

Conversely, the 1-year return is negative at -18.69%, underperforming the Sensex’s -6.40%. Over longer periods, Syncom has outpaced the benchmark substantially, with 3-year, 5-year, and 10-year returns of 149.06%, 120.92%, and an impressive 684.16% respectively, compared to Sensex returns of 23.62%, 51.05%, and 195.54% over the same durations.

This long-term outperformance may justify some premium, but the recent valuation upgrade to expensive suggests that much of this growth is already priced in, raising questions about future upside potential.

Price Movement and Market Capitalisation

On 26 May 2026, Syncom Formulations closed at ₹15.84, up 10.54% from the previous close of ₹14.33. The stock traded within a range of ₹14.57 to ₹16.51 during the day, reflecting heightened investor interest. The 52-week high and low stand at ₹23.46 and ₹10.21 respectively, indicating significant volatility over the past year.

Despite the recent rally, the company remains classified as a micro-cap, which often entails higher risk and lower liquidity compared to larger peers. This classification may contribute to the valuation premium as investors seek growth opportunities in smaller pharmaceutical firms.

Mojo Score and Rating Update

MarketsMOJO’s latest assessment downgraded Syncom Formulations from a Hold to a Sell rating on 9 February 2026, reflecting concerns over valuation and risk-reward balance. The company’s Mojo Score stands at 42.0, which is relatively low and consistent with the Sell grade. This downgrade signals caution for investors, especially given the stock’s elevated multiples and micro-cap status.

Investors should weigh the company’s strong operational metrics and historical returns against the current expensive valuation and recent price volatility. The downgrade suggests that the stock may face headwinds unless it can sustain earnings growth to justify its premium multiples.

Conclusion: Valuation Premium Demands Careful Consideration

Syncom Formulations’ shift from fair to expensive valuation territory, as evidenced by its P/E and P/BV ratios, marks a critical juncture for investors. While the company boasts strong profitability metrics and impressive long-term returns, the recent price appreciation and micro-cap classification introduce heightened risk.

Comparisons with peers reveal that Syncom is not the most expensive stock in its sector but has moved beyond a comfortable valuation range. The low PEG ratio hints at expected growth, yet the downgrade to a Sell rating by MarketsMOJO underscores the need for caution.

For investors considering exposure to Syncom Formulations, it is essential to balance the company’s growth potential against its stretched valuation and market risks. Monitoring upcoming earnings and sector developments will be key to realising whether the current premium is sustainable or if a reversion to fairer valuations is imminent.

Only Rs. 20,999 - Get MojoOne + Stock of the Week for 3 Years Get 71% Off →